disorders, including acute ischemic stroke and catheter occlusion (CO); NU172, a direct thrombin inhibitor in Phase I development for use as a short-acting anticoagulant during medical or surgical procedures, and preclinical candidate NU206 for the treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo has research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities. (Source: 10-K)